Vaccinex Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vaccinex Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0481
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vaccinex Inc (Vaccinex) is a clinical-stage biotechnology company that discovers and develops targeted biotherapeutics to treat neurodegenerative diseases, cancer and autoimmune disorders. The company’s lead platform technologies include antibody platform and ActivMAb, SEMA4D, and antibody discovery platform. Vaccinex through its antibody platform develops its lead product candidate VX15, for the treatment of various indications such as neurodegenerative diseases, neuroinflammatory and cancer. The company also develops VX5 that is in preclinical development for the treatment of autoimmune disorders. It has partnership with biotechnology and biopharmaceutical companies to enhance its product candidates. Vaccinex is headquartered in Rochester, New York, the US.

Vaccinex Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaccinex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vaccinex Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Vaccinex Raises USD6 Million in Venture Financing 10
Partnerships 11
Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 11
Vaccinex Enters into Agreement with Children’s Hospital of Philadelphia 12
Vaccinex Enters into Agreement with Emory University 13
Vaccinex Enters into Agreement with Merck 14
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 15
Vaccinex Enters into Research Agreement with Janssen Research & Development 16
Licensing Agreements 17
Surface Oncology Enters into Research and License Option Agreement with Vaccinex 17
VX3 Enters into Licensing Agreement with Vaccinex 18
Vaccinex Enters into Licensing Agreement with biOasis Technologies 19
Equity Offering 20
Vaccinex Pharma Files Registration Statement to Raise up to USD46 Million in IPO of Shares 20
Vaccinex Inc – Key Competitors 21
Vaccinex Inc – Key Employees 22
Vaccinex Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Product News 24
10/26/2017: Vaccinex Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung) 24
Clinical Trials 25
Apr 24, 2017: Vaccinex Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease) 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Vaccinex Inc, Pharmaceuticals & Healthcare, Key Facts 2
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaccinex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaccinex Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vaccinex Raises USD6 Million in Venture Financing 10
Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 11
Vaccinex Enters into Agreement with Children’s Hospital of Philadelphia 12
Vaccinex Enters into Agreement with Emory University 13
Vaccinex Enters into Agreement with Merck 14
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 15
Vaccinex Enters into Research Agreement with Janssen Research & Development 16
Surface Oncology Enters into Research and License Option Agreement with Vaccinex 17
VX3 Enters into Licensing Agreement with Vaccinex 18
Vaccinex Enters into Licensing Agreement with biOasis Technologies 19
Vaccinex Pharma Files Registration Statement to Raise up to USD46 Million in IPO of Shares 20
Vaccinex Inc, Key Competitors 21
Vaccinex Inc, Key Employees 22

List of Figures
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaccinex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Vaccinex Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • KELAG-Karntner Elektrizitats-Aktiengesellschaft:企業の戦略的SWOT分析
    KELAG-Karntner Elektrizitats-Aktiengesellschaft - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Jiangsu Jiuding New Material Co., Ltd. (002201):企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co., Ltd. (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • W. R. Grace & Co:企業の戦略・SWOT・財務情報
    W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report Summary W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • View Inc:電力:M&Aディール及び事業提携情報
    Summary View Inc (View), formerly Soladigm, Inc. is a clean technology company that offers smart glass systems. The company’s View Dynamic Glass controls light and heat entering the building. View Dynamic Glass uses intelligent engine that adapts to the environment, responds to users’ preferences an …
  • BioSyent Inc (RX):企業の財務・戦略的SWOT分析
    Summary BioSyent Inc (BioSyent), formerly Hedley Technologies Inc is a specialty pharmaceutical company that offers in-licensing or acquiring innovative pharmaceutical products and technologies to enhance human health. The company’s products include Aguettant System for pre-filled syringes, FeraMAX …
  • St. Jude Medical, Inc.:企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Beam Suntory Inc.:企業の戦略・SWOT・財務分析
    Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report Summary Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Oxurion NV (THR):製薬・医療:M&Aディール及び事業提携情報
    Summary Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreo …
  • Epic Systems Corp:企業の戦略的SWOT分析
    Epic Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pan American Silver Corp:企業の戦略・SWOT・財務情報
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platf …
  • UCB S.A.:企業のM&A・事業提携・投資動向
    UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • BEKB | BCBE Private Banking:企業の戦略・SWOT・財務分析
    BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report Summary BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Voya Financial Inc:企業の戦略・SWOT・財務分析
    Voya Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Voya Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Barnes & Noble, Inc.:企業の戦略・SWOT・財務情報
    Barnes & Noble, Inc. - Strategy, SWOT and Corporate Finance Report Summary Barnes & Noble, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Rizzani de Eccher S.p.A.:企業の戦略・SWOT・財務情報
    Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Adana Cimento Sanayii Tas:企業の戦略・SWOT・財務分析
    Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report Summary Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆